DOXYCYCLINE HYCLATE ( DrugBank: Doxycycline )


3 diseases
IDDisease name (Link within this page)Number of trials
23Prion disease1
96Crohn disease1
227Osler disease1

23. Prion disease


Clinical trials : 4 Drugs : 5 - (DrugBank : 2) / Drug target gene : 0 - Drug target pathway : 0
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-022233-28-IT
(EUCTR)
20/06/201105/03/2012Fatal familial insomnia: preventive treatment with doxycycline of at risk individuals - Doxycycline in FFI individuals Subjects born between 1958 and 1969 belonging to the Treviso FFI family, tested previously for Prion D178N/129M mutation
MedDRA version: 14.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: BASSADO
INN or Proposed INN: DOXYCYCLINE HYCLATE
IST. DI RICERCHE FARMACOLOG. M. NEGRINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy

96. Crohn disease


Clinical trials : 2,400 Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-001137-99-GB
(EUCTR)
28/04/200927/11/2008 CHANGE TO: A PILOT RANDOMISED STUDY TO COMPARE COMBINATION ANTIBIOTIC THERAPY (CIPROFLOXACIN AND DOXYCYCLINE) WITH STANDARD THERAPY (BUDESONIDE) IN THE TREATMENT OF ACTIVE CROHN'S DISEASE - Combination antibiotic therapy in treatment of active Crohn's disease CHANGE TO: A PILOT RANDOMISED STUDY TO COMPARE COMBINATION ANTIBIOTIC THERAPY (CIPROFLOXACIN AND DOXYCYCLINE) WITH STANDARD THERAPY (BUDESONIDE) IN THE TREATMENT OF ACTIVE CROHN'S DISEASE - Combination antibiotic therapy in treatment of active Crohn's disease Crohn's Disease
MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders
Product Name: Ciprofloxacin
Product Code: PL 20532/0012
INN or Proposed INN: Ciprofloxacin hydrochloride
Product Name: Budesonide
Product Code: PL 17901/0122
INN or Proposed INN: Budesonide
Other descriptive name: Entocort CR
Trade Name: DOXYCYCLINE
Product Name: DOXYCYCLINE
INN or Proposed INN: DOXYCYCLINE HYCLATE
Other descriptive name: DOXYCYCLINE
Trade Name: HYDROXYCHLOROQUINE
Product Name: HYDROXYCHLOROQUINE SULPHATE
INN or Proposed INN: HYDROXYCHLOROQUINE SULPHATE
Other descriptive name: PLAQUENIL
Royal Liverpool & Broadgreen University Hospitals TrustUniversity of LiverpoolNot Recruiting Female: yes
Male: yes
100 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom

227. Osler disease


Clinical trials : 54 Drugs : 73 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03397004
(ClinicalTrials.gov)
September 12, 201821/11/2017Doxycycline for Hereditary Hemorrhagic TelangiectasiaDoxycycline Crossover Trial for Hereditary Hemorrhagic TelangiectasiaHereditary Hemorrhagic Telangiectasia (HHT)Drug: Doxycycline Hyclate;Drug: PlaceboUnity Health TorontoBarrow Neurological Institute;Duke University;Feinstein Institute for Medical Research;University of Pittsburgh;Sunnybrook Health Sciences CentreActive, not recruiting18 YearsN/AAll30Phase 2Canada